# Baziel van Engelen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2331136/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 508 papers | 21,037 citations | 9254 74 h-index | 19169 118 g-index |
| 527 all docs | 527 docs citations | 527 times ranked | 17009 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2. Nature Genetics, 2012, 44, 1370-1374. | 9.4 | 582 |
| 2 | The clinical spectrum of neuralgic amyotrophy in 246 cases. Brain, 2006, 129, 438-450. | 3.7 | 572 |
| 3 | Performance of near-infrared spectroscopy in measuring local O<sub>2</sub> consumption and blood flow in skeletal muscle. Journal of Applied Physiology, 2001, 90, 511-519. | 1.2 | 477 |
| 4 | Skeletal Muscle Ultrasound: Correlation Between Fibrous Tissue and Echo Intensity. Ultrasound in Medicine and Biology, 2009, 35, 443-446. | 0.7 | 456 |
| 5 | Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain, 2010, 133, 655-670. | 3.7 | 356 |
| 6 | Autoantibody profiles in the sera of European patients with myositis. Annals of the Rheumatic Diseases, 2001, 60, 116-123. | 0.5 | 330 |
| 7 | Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Annals of the Rheumatic Diseases, 2006, 65, 1635-1638. | 0.5 | 289 |
| 8 | Population-based incidence and prevalence of facioscapulohumeral dystrophy. Neurology, 2014, 83, 1056-1059. | 1.5 | 278 |
| 9 | A second missense mutation in the mitochondrial ATPase 6 gene in Leigh's syndrome. Annals of Neurology, 1993, 34, 410-412. | 2.8 | 239 |
| 10 | Clinical applications of high-density surface EMG: A systematic review. Journal of Electromyography and Kinesiology, 2006, 16, 586-602. | 0.7 | 236 |
| 11 | The assessment of fatigue: Psychometric qualities and norms for the Checklist individual strength. Journal of Psychosomatic Research, 2017, 98, 40-46. | 1.2 | 222 |
| 12 | Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain, 2000, 123, 908-919. | 3.7 | 219 |
| 13 | Clinical neurophysiology of fatigue. Clinical Neurophysiology, 2008, 119, 2-10. | 0.7 | 207 |
| 14 | Autoantibodies to cytosolic 5â€²â€nucleotidase 1A in inclusion body myositis. Annals of Neurology, 2013, 73, 397-407. | 2.8 | 206 |
| 15 | Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Medicine, 2003, 29, 1121-1125. | 3.9 | 202 |
| 16 | The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85. | 1.1 | 200 |
| 17 | Mutations in DNMT3B Modify Epigenetic Repression of the D4Z4 Repeat and the Penetrance of Facioscapulohumeral Dystrophy. American Journal of Human Genetics, 2016, 98, 1020-1029. | 2.6 | 188 |
| 18 | Epidemiology of inclusion body myositis in the Netherlands: A nationwide study. Neurology, 2000, 55, 1385-1388. | 1.5 | 187 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. Cell Metabolism, 2015, 22, 399-407. | 7.2 | 180 |
| 20 | A weak balance: the contribution of muscle weakness to postural instability and falls. Nature Clinical Practice Neurology, 2008, 4, 504-515. | 2.7 | 179 |
| 21 | Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation, 2007, 88, 1452-1464. | 0.5 | 177 |
| 22 | Pain in Ehlers-Danlos Syndrome Is Common, Severe, and Associated with Functional Impairment. Journal of Pain and Symptom Management, 2010, 40, 370-378. | 0.6 | 176 |
| 23 | Common epigenetic changes of D4Z4 in contraction-dependent and contraction-independent FSHD. Human Mutation, 2009, 30, 1449-1459. | 1.1 | 172 |
| 24 | Nuclear envelope alterations in fibroblasts from LGMD1B patients carrying nonsense Y259X heterozygous or homozygous mutation in lamin A/C gene. Experimental Cell Research, 2003, 291, 352-362. | 1.2 | 169 |
| 25 | Mutations in RYR1 are a common cause of exertional myalgia and rhabdomyolysis. Neuromuscular Disorders, 2013, 23, 540-548. | 0.3 | 169 |
| 26 | A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of Neurology, 2008, 255, 1400-1404. | 1.8 | 158 |
| 27 | Causes and consequences of cerebral small vessel disease. The RUN DMC study: a prospective cohort study. Study rationale and protocol. BMC Neurology, 2011, 11, 29. | 0.8 | 154 |
| 28 | Neuralgic amyotrophy and hepatitis E virus infection. Neurology, 2014, 82, 498-503. | 1.5 | 150 |
| 29 | Cerebrotendinous Xanthomatosis: The Spectrum of Imaging Findings and the Correlation with Neuropathologic Findings. Radiology, 2000, 217, 869-876. | 3.6 | 147 |
| 30 | Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations. European Neurology, 2003, 50, 10-15. | 0.6 | 143 |
| 31 | Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2010, 87, 842-847. | 2.6 | 143 |
| 32 | Neuromuscular involvement in various types of Ehlersâ€“Danlos syndrome. Annals of Neurology, 2009, 65, 687-697. | 2.8 | 141 |
| 33 | Fatigue Is a Frequent and Clinically Relevant Problem in Ehlers-Danlos Syndrome. Seminars in Arthritis and Rheumatism, 2010, 40, 267-274. | 1.6 | 131 |
| 34 | Strength training and aerobic exercise training for muscle disease. The Cochrane Library, 2013, , CD003907. | 1.5 | 130 |
| 35 | Inter-individual differences in CpG methylation at D4Z4 correlate with clinical variability in FSHD1 and FSHD2. Human Molecular Genetics, 2015, 24, 659-669. | 1.4 | 130 |
| 36 | Best practice guidelines and recommendations on the molecular diagnosis of myotonic dystrophy types 1 and 2. European Journal of Human Genetics, 2012, 20, 1203-1208. | 1.4 | 129 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. Journal of Neurology, Neurosurgery and Psychiatry, 1999, 66, 569-574. | 0.9 | 128 |
| 38 | Acceleration in the Rate of CNS Remyelination in Lysolecithin-Induced Demyelination. Journal of Neuroscience, 1998, 18, 2498-2505. | 1.7 | 127 |
| 39 | Distinct Disease Phases in Muscles of Facioscapulohumeral Dystrophy Patients Identified by MR Detected Fat Infiltration. PLoS ONE, 2014, 9, e85416. | 1.1 | 125 |
| 40 | Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2Â antigen. Annals of the Rheumatic Diseases, 2006, 65, 242-245. | 0.5 | 124 |
| 41 | Protein S-100B, neuron-specific enolase (NSE), myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF) and blood of neurological patients. Brain Research Bulletin, 2003, 61, 261-264. | 1.4 | 122 |
| 42 | Inclusion body myositis. Journal of Neurology, 2005, 252, 1448-1454. | 1.8 | 118 |
| 43 | In vivo quantitative near-infrared spectroscopy in skeletal muscle during incremental isometric handgrip exercise. Clinical Physiology and Functional Imaging, 2002, 22, 210-217. | 0.5 | 117 |
| 44 | Nucleoplasmic LAP2Î±â€“lamin A complexes are required to maintain a proliferative state in human fibroblasts. Journal of Cell Biology, 2007, 176, 163-172. | 2.3 | 117 |
| 45 | Disease specificity of autoantibodies to cytosolic 5â€²-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. Annals of the Rheumatic Diseases, 2016, 75, 696-701. | 0.5 | 116 |
| 46 | Consensus-based care recommendations for adults with myotonic dystrophy type 1. Neurology: Clinical Practice, 2018, 8, 507-520. | 0.8 | 115 |
| 47 | MSH3 modifies somatic instability and disease severity in Huntingtonâ€™s and myotonic dystrophy type 1. Brain, 2019, 142, 1876-1886. | 3.7 | 114 |
| 48 | Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet Journal of Rare Diseases, 2012, 7, 88. | 1.2 | 112 |
| 49 | Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathologica, 2015, 129, 611-624. | 3.9 | 112 |
| 50 | <scp>RYR</scp>1â€related myopathies: a wide spectrum of phenotypes throughout life. European Journal of Neurology, 2015, 22, 1094-1112. | 1.7 | 111 |
| 51 | Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Annals of Neurology, 2002, 51, 369-372. | 2.8 | 108 |
| 52 | Both aerobic exercise and cognitive-behavioral therapy reduce chronic fatigue in FSHD. Neurology, 2014, 83, 1914-1922. | 1.5 | 106 |
| 53 | The development of a model of fatigue in neuromuscular disorders: A longitudinal study. Journal of Psychosomatic Research, 2007, 62, 571-579. | 1.2 | 102 |
| 54 | Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. Annals of Neurology, 1992, 32, 834-835. | 2.8 | 98 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Annals of the Rheumatic Diseases, 2000, 59, 141-142. | 0.5 | 97 |
| 56 | Difference in distribution of muscle weakness between myasthenia gravis and the Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 766-768. | 0.9 | 97 |
| 57 | Measurement of the Energy-Generating Capacity of Human Muscle Mitochondria: Diagnostic Procedure and Application to Human Pathology. Clinical Chemistry, 2006, 52, 860-871. | 1.5 | 96 |
| 58 | Intrinsic Epigenetic Regulation of the D4Z4 Macrosatellite Repeat in a Transgenic Mouse Model for FSHD. PLoS Genetics, 2013, 9, e1003415. | 1.5 | 95 |
| 59 | Cognitive behavioural therapy with optional graded exercise therapy in patients with severe fatigue with myotonic dystrophy type 1: a multicentre, single-blind, randomised trial. Lancet Neurology, The, 2018, 17, 671-680. | 4.9 | 95 |
| 60 | Relation between muscle fiber conduction velocity and fiber size in neuromuscular disorders. Journal of Applied Physiology, 2006, 100, 1837-1841. | 1.2 | 93 |
| 61 | Open-Label Trial of Anti-TNF-Î± in Dermato- and Polymyositis Treated Concomitantly with Methotrexate. European Neurology, 2008, 59, 159-163. | 0.6 | 92 |
| 62 | Oculopharyngeal muscular dystrophy with limb girdle weakness as major complaint. Journal of Neurology, 2003, 250, 1307-1312. | 1.8 | 91 |
| 63 | Living with myotonic dystrophy; what can be learned from couples? a qualitative study. BMC Neurology, 2011, 11, 86. | 0.8 | 91 |
| 64 | Localization of 4q35.2 to the nuclear periphery: is FSHD a nuclear envelope disease?. Human Molecular Genetics, 2004, 13, 1857-1871. | 1.4 | 90 |
| 65 | Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. Metabolism: Clinical and Experimental, 1999, 48, 233-238. | 1.5 | 89 |
| 66 | The Epidemiology of Neuromuscular Disorders: A Comprehensive Overview of the Literature. Journal of Neuromuscular Diseases, 2015, 2, 73-85. | 1.1 | 89 |
| 67 | Clinical and serological characteristics of 125 Dutch myositis patients. Journal of Neurology, 2002, 249, 69-75. | 1.8 | 88 |
| 68 | Experienced and physiological fatigue in neuromuscular disorders. Clinical Neurophysiology, 2007, 118, 292-300. | 0.7 | 88 |
| 69 | 171st ENMC International Workshop: Standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2010, 20, 471-475. | 0.3 | 88 |
| 70 | Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology, 2011, 50, 2206-2213. | 0.9 | 88 |
| 71 | Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). The Cochrane Library, 2009, , CD006976. | 1.5 | 87 |
| 72 | Presence of Diarrhea and Absence of Tendon Xanthomas in Patients With Cerebrotendinous Xanthomatosis. Archives of Neurology, 2000, 57, 520. | 4.9 | 86 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet Journal of Rare Diseases, 2012, 7, 73. | 1.2 | 86 |
| 74 | The cognitive profile of myotonic dystrophy type 1:ÂA systematic review and meta-analysis. Cortex, 2017, 95, 143-155. | 1.1 | 82 |
| 75 | Autoantibodies directed to novel components of the PM/Scl complex, the human exosome. Arthritis Research, 2002, 4, 134. | 2.0 | 81 |
| 76 | What's in a name? The clinical features of facioscapulohumeral muscular dystrophy. Practical Neurology, 2016, 16, 201-207. | 0.5 | 81 |
| 77 | Effect of Mexiletine on Muscle Stiffness in Patients With Nondystrophic Myotonia Evaluated Using Aggregated N-of-1 Trials. JAMA - Journal of the American Medical Association, 2018, 320, 2344. | 3.8 | 81 |
| 78 | Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. Journal of Hepatology, 2017, 67, 925-932. | 1.8 | 80 |
| 79 | Protein Complexes in the Archaeon Methanothermobacter thermautotrophicus Analyzed by Blue Native/SDS-PAGE and Mass Spectrometry. Molecular and Cellular Proteomics, 2005, 4, 1653-1663. | 2.5 | 79 |
| 80 | Is fatigue a disease-specific or generic symptom in chronic medical conditions?. Health Psychology, 2018, 37, 530-543. | 1.3 | 79 |
| 81 | Clinical and molecular overlap between myopathies and inherited connective tissue diseases. Neuromuscular Disorders, 2008, 18, 843-856. | 0.3 | 76 |
| 82 | Brain imaging in myotonic dystrophy type 1. Neurology, 2017, 89, 960-969. | 1.5 | 76 |
| 83 | Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-Î±: Long-Term Follow-Up. European Neurology, 2004, 52, 61-63. | 0.6 | 75 |
| 84 | Clinical phenotype and outcome of hepatitis E virusâ€“associated neuralgic amyotrophy. Neurology, 2017, 89, 909-917. | 1.5 | 75 |
| 85 | Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neurology, 2017, 89, 2057-2065. | 1.5 | 72 |
| 86 | Leukoencephalopathy with swelling in children and adolescents: MRI patterns and differential diagnosis. Neuroradiology, 1995, 37, 679-686. | 1.1 | 71 |
| 87 | A novel late-onset axial myopathy associated with mutations in the skeletal muscle ryanodine receptor (RYR1) gene. Journal of Neurology, 2013, 260, 1504-1510. | 1.8 | 71 |
| 88 | Cytosolic 5â€²-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Annals of the Rheumatic Diseases, 2017, 76, 862-868. | 0.5 | 71 |
| 89 | Genetic determinants of disease severity in the myotonic dystrophy type 1 OPTIMISTIC cohort. Neurology, 2019, 93, e995-e1009. | 1.5 | 71 |
| 90 | Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2007, 254, 931-940. | 1.8 | 69 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Long-Term Pain, Fatigue, and Impairment in Neuralgic Amyotrophy. Archives of Physical Medicine and Rehabilitation, 2009, 90, 435-439. | 0.5 | 69 |
| 92 | In tandem analysis of CLCN1 and SCN4A greatly enhances mutation detection in families with non-dystrophic myotonia. European Journal of Human Genetics, 2008, 16, 921-929. | 1.4 | 68 |
| 93 | Ocular and Systemic Manifestations of Cerebrotendinous Xanthomatosis. American Journal of Ophthalmology, 1995, 120, 597-604. | 1.7 | 67 |
| 94 | Drug treatment for myotonia. The Cochrane Library, 2006, , CD004762. | 1.5 | 66 |
| 95 | Increased plasticity of the nuclear envelope and hypermobility of telomeres due to the loss of Aâ€“type lamins. Biochimica Et Biophysica Acta - General Subjects, 2010, 1800, 448-458. | 1.1 | 65 |
| 96 | Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. Journal of Neurology, 1999, 246, 623-625. | 1.8 | 64 |
| 97 | Generation of Isogenic D4Z4 Contracted and Noncontracted Immortal Muscle Cell Clones from a Mosaic Patient. American Journal of Pathology, 2012, 181, 1387-1401. | 1.9 | 63 |
| 98 | Propagation disturbance of motor unit action potentials during transient paresis in generalized myotonia: A high-density surface EMG study. Brain, 2001, 124, 352-360. | 3.7 | 62 |
| 99 | Balance control in patients with distal versus proximal muscle weakness. Neuroscience, 2009, 164, 1876-1886. | 1.1 | 61 |
| 100 | Quantitative MRI reveals decelerated fatty infiltration in muscles of active FSHD patients. Neurology, 2016, 86, 1700-1707. | 1.5 | 61 |
| 101 | Identifying deficits in balance control following vestibular or proprioceptive loss using posturographic analysis of stance tasks. Clinical Neurophysiology, 2008, 119, 2338-2346. | 0.7 | 60 |
| 102 | High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome; an add-on study. European Journal of Pediatrics, 1994, 153, 762-769. | 1.3 | 59 |
| 103 | TDP-43 accumulation is common in myopathies with rimmed vacuoles. Acta Neuropathologica, 2009, 117, 209-211. | 3.9 | 59 |
| 104 | Variability in fibre properties in paralysed human quadriceps muscles and effects of training. Pflugers Archiv European Journal of Physiology, 2003, 445, 734-740. | 1.3 | 58 |
| 105 | Effects of Mindfulness-Based Stress Reduction on the Mental Health of Clinical Clerkship Students: A Cluster-Randomized Controlled Trial. Academic Medicine, 2017, 92, 1012-1021. | 0.8 | 56 |
| 106 | The mitochondrial 13513G>A mutation is most frequent in Leigh syndrome combined with reduced complex I activity, optic atrophy and/or Wolffâ€“Parkinsonâ€“White. European Journal of Human Genetics, 2007, 15, 155-161. | 1.4 | 55 |
| 107 | A frameshift mutation in LRSAM1 is responsible for a dominant hereditary polyneuropathy. Human Molecular Genetics, 2012, 21, 358-370. | 1.4 | 55 |
| 108 | MRI in sarcoglycanopathies: a large international cohort study. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 72-77. | 0.9 | 55 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | A locus on chromosome 15q for a dominantly inherited nemaline myopathy with core-like lesions. Brain, 2003, 126, 1545-1551. | 3.7 | 54 |
| 110 | Mitochondrial enzymes discriminate between mitochondrial disorders and chronic fatigue syndrome. Mitochondrion, 2011, 11, 735-738. | 1.6 | 54 |
| 111 | Mutationâ€specific effects on thin filament length in thin filament myopathy. Annals of Neurology, 2016, 79, 959-969. | 2.8 | 54 |
| 112 | Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers. Journal of Neurology, 2018, 265, 2646-2655. | 1.8 | 54 |
| 113 | Benzodiazepine Withdrawal Reaction in Two Children following Discontinuation of Sedation with Midazolam. Annals of Pharmacotherapy, 1993, 27, 579-581. | 0.9 | 53 |
| 114 | Fuel utilization in patients with very long-chain acyl-coa dehydrogenase deficiency. Annals of Neurology, 2004, 56, 279-283. | 2.8 | 53 |
| 115 | Fatigue is associated with muscle weakness in Ehlers-Danlos syndrome: an explorative study. Physiotherapy, 2011, 97, 170-174. | 0.2 | 53 |
| 116 | Guidelines on clinical presentation and management of nondystrophic myotonias. Muscle and Nerve, 2020, 62, 430-444. | 1.0 | 53 |
| 117 | Calcium regulation and muscle disease. Journal of Muscle Research and Cell Motility, 2002, 23, 59-63. | 0.9 | 51 |
| 118 | Diminished central activation during maximal voluntary contraction in chronic fatigue syndrome. Clinical Neurophysiology, 2004, 115, 2518-2524. | 0.7 | 51 |
| 119 | Myositis-specific autoantibodies: overview and recent developments. Current Opinion in Rheumatology, 2001, 13, 476-482. | 2.0 | 50 |
| 120 | Transferrin and Apolipoprotein C-III Isofocusing Are Complementary in the Diagnosis of N- and O-Glycan Biosynthesis Defects. Clinical Chemistry, 2007, 53, 180-187. | 1.5 | 50 |
| 121 | Gastrointestinal involvement is frequent in Myotonic Dystrophy type 2. Neuromuscular Disorders, 2008, 18, 646-649. | 0.3 | 50 |
| 122 | Cognitive behaviour therapy plus aerobic exercise training to increase activity in patients with myotonic dystrophy type 1 (DM1) compared to usual care (OPTIMISTIC): study protocol for randomised controlled trial. Trials, 2015, 16, 224. | 0.7 | 49 |
| 123 | A decline in PABPN1 induces progressive muscle weakness in Oculopharyngeal muscle dystrophy and in muscle aging. Aging, 2013, 5, 412-426. | 1.4 | 49 |
| 124 | Falls in patients with neuromuscular disorders. Journal of the Neurological Sciences, 2006, 251, 87-90. | 0.3 | 48 |
| 125 | Sensory Nerve Conduction Studies in Neuralgic Amyotrophy. American Journal of Physical Medicine and Rehabilitation, 2009, 88, 941-946. | 0.7 | 48 |
| 126 | Correlation analysis of clinical parameters with epigenetic modifications in the DUX4 promoter in FSHD. Epigenetics, 2012, 7, 579-584. | 1.3 | 48 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders. Journal of Neurology, 2018, 265, 1803-1809. | 1.8 | 48 |
| 128 | Treatment of the inflammatory myopathies: update and practical recommendations. Expert Opinion on Pharmacotherapy, 2009, 10, 1183-1190. | 0.9 | 47 |
| 129 | Joint hypermobility as a distinctive feature in the differential diagnosis of myopathies. Journal of Neurology, 2009, 256, 13-27. | 1.8 | 47 |
| 130 | Quantitative muscle ultrasound versus quantitative magnetic resonance imaging in facioscapulohumeral dystrophy. Muscle and Nerve, 2014, 50, 968-975. | 1.0 | 47 |
| 131 | Recognizing the tenascinâ€X deficient type of Ehlersâ€“Danlos syndrome: a crossâ€sectional study in 17 patients. Clinical Genetics, 2017, 91, 411-425. | 1.0 | 46 |
| 132 | Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development. Human Molecular Genetics, 2019, 28, 1064-1075. | 1.4 | 46 |
| 133 | Effect of aerobic exercise training and cognitive behavioural therapy on reduction of chronic fatigue in patients with facioscapulohumeral dystrophy: protocol of the FACTS-2-FSHD trial. BMC Neurology, 2010, 10, 56. | 0.8 | 45 |
| 134 | Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Research and Therapy, 2014, 16, R111. | 1.6 | 45 |
| 135 | Possible mechanisms of muscle cramp from temporal and spatial surface EMG characteristics. Journal of Applied Physiology, 2000, 88, 1698-1706. | 1.2 | 44 |
| 136 | Strength training and aerobic exercise training for muscle disease. The Cochrane Library, 2019, 2019, CD003907. | 1.5 | 44 |
| 137 | Permanent Loss of Cervical Spinal Cord Function Associated with the Posterior Approach. Anesthesia and Analgesia, 2006, 102, 330-331. | 1.1 | 43 |
| 138 | Vestibular and proprioceptive influences on trunk movements during quiet standing. Neuroscience, 2009, 161, 904-914. | 1.1 | 43 |
| 139 | Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR in Biomedicine, 2010, 23, 563-568. | 1.6 | 43 |
| 140 | Poor sleep quality and fatigue but no excessive daytime sleepiness in myotonic dystrophy type 2. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, 963-967. | 0.9 | 43 |
| 141 | Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Research, 1994, 19, 181-190. | 0.8 | 42 |
| 142 | Quantitative near-infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Annals of Neurology, 1999, 46, 667-670. | 2.8 | 42 |
| 143 | Disease Course of Charcot-Marie-Tooth Disease Type 2. Archives of Neurology, 2003, 60, 823. | 4.9 | 42 |
| 144 | Fasciculation Potentials in High-Density Surface EMG. Journal of Clinical Neurophysiology, 2007, 24, 301-307. | 0.9 | 42 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | Dysarthria and dysphagia are highly prevalent among various types of neuromuscular diseases. Disability and Rehabilitation, 2014, 36, 1285-1289. | 0.9 | 42 |
| 146 | HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor. Human Immunology, 2001, 62, 809-813. | 1.2 | 40 |
| 147 | Rhabdomyolysis Caused by an Inherited Metabolic Disease: Very Long-chain Acyl-CoA Dehydrogenase Deficiency. American Journal of Medicine, 2006, 119, 176-179. | 0.6 | 40 |
| 148 | Needle Electromyographic Findings in 98 Patients with Myositis. European Neurology, 2006, 55, 183-188. | 0.6 | 40 |
| 149 | Referral of patients with neuromuscular disease to occupational therapy, physical therapy and speech therapy: Usual practice versus multidisciplinary advice. Disability and Rehabilitation, 2007, 29, 717-726. | 0.9 | 40 |
| 150 | Facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2009, 22, 539-542. | 1.8 | 40 |
| 151 | Postural instability in Charcot-Marie-Tooth type 1A patients is strongly associated with reduced somatosensation. Gait and Posture, 2010, 31, 483-488. | 0.6 | 40 |
| 152 | Deregulation of the ubiquitin-proteasome system is the predominant molecular pathology in OPMD animal models and patients. Skeletal Muscle, 2011, 1, 15. | 1.9 | 40 |
| 153 | Sporadic late-onset nemaline myopathy with MGUS. Neurology, 2014, 83, 2133-2139. | 1.5 | 40 |
| 154 | Prevalence and mutation spectrum of skeletal muscle channelopathies in the Netherlands. Neuromuscular Disorders, 2018, 28, 402-407. | 0.3 | 40 |
| 155 | Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy. Clinical Genetics, 2020, 97, 799-814. | 1.0 | 40 |
| 156 | The Dutch neuromuscular database CRAMP (Computer Registry of All Myopathies and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 302 Td (Po | 0.3 | 39 |
| 157 | Different types of fatigue in patients with facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I. Experienced fatigue and physiological fatigue. Neurological Sciences, 2008, 29, 238-240. | 0.9 | 39 |
| 158 | Molecular therapy in myotonic dystrophy: focus on RNA gain-of-function. Human Molecular Genetics, 2010, 19, R90-R97. | 1.4 | 39 |
| 159 | Early onset facioscapulohumeral dystrophy â€“ a systematic review using individual patient data. Neuromuscular Disorders, 2017, 27, 1077-1083. | 0.3 | 39 |
| 160 | Muscle ultrasound measurements and functional muscle parameters in non-dystrophic myotonias suggest structural muscle changes. Neuromuscular Disorders, 2009, 19, 462-467. | 0.3 | 38 |
| 161 | Research priorities of patients with neuromuscular disease. Disability and Rehabilitation, 2013, 35, 405-412. | 0.9 | 38 |
| 162 | Muscle MRI in a large cohort of patients with oculopharyngeal muscular dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 576-585. | 0.9 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders. Journal of Neurology, 2005, 252, 534-537. | 1.8 | 36 |
| 164 | Psychiatric disorders appear equally in patients with myotonic dystrophy, facioscapulohumeral dystrophy, and hereditary motor and sensory neuropathy type I. Acta Neurologica Scandinavica, 2007, 115, 265-270. | 1.0 | 36 |
| 165 | Sarcomeric dysfunction contributes to muscle weakness in facioscapulohumeral muscular dystrophy. Neurology, 2013, 80, 733-737. | 1.5 | 36 |
| 166 | Second IVIg course in Guillainâ€BarrÃ© syndrome patients with poor prognosis (SIDâ€GBS trial): Protocol for a doubleâ€blind randomized, placeboâ€controlled clinical trial. Journal of the Peripheral Nervous System, 2018, 23, 210-215. | 1.4 | 36 |
| 167 | Decreased immunoglobulin class switching in nijmegen breakage syndrome due to the DNA repair defect. Human Immunology, 2001, 62, 1324-1327. | 1.2 | 35 |
| 168 | Brody syndrome: A clinically heterogeneous entity distinct from Brody disease. Neuromuscular Disorders, 2012, 22, 944-954. | 0.3 | 35 |
| 169 | The Radboud Dysarthria Assessment: Development and Clinimetric Evaluation. Folia Phoniatrica Et Logopaedica, 2017, 69, 143-153. | 0.5 | 35 |
| 170 | Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Current Opinion in Rheumatology, 2004, 16, 692-9. | 2.0 | 35 |
| 171 | Idiopathic Neuralgic Amyotrophy in Children. A Distinct Phenotype Compared to the Adult Form. Neuropediatrics, 2000, 31, 328-332. | 0.3 | 34 |
| 172 | Lower extremity muscle pathology in myotonic dystrophy type 1 assessed by quantitative MRI. Neurology, 2019, 92, e2803-e2814. | 1.5 | 34 |
| 173 | Second intravenous immunoglobulin dose in patients with Guillain-BarrÃ© syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 275-283. | 4.9 | 34 |
| 174 | Muscle-fiber conduction velocity and electromyography as diagnostic tools in patients with suspected inflammatory myopathy: A prospective study. Muscle and Nerve, 2004, 29, 46-50. | 1.0 | 33 |
| 175 | Titin-based stiffening of muscle fibers in Ehlers-Danlos Syndrome. Journal of Applied Physiology, 2012, 112, 1157-1165. | 1.2 | 33 |
| 176 | Skeletal muscle imaging in facioscapulohumeral muscular dystrophy, pattern and asymmetry of individual muscle involvement. Neuromuscular Disorders, 2014, 24, 1087-1096. | 0.3 | 33 |
| 177 | A family-based study into penetrance in facioscapulohumeral muscular dystrophy type 1. Neurology, 2018, 91, e444-e454. | 1.5 | 33 |
| 178 | Central adaptations during repetitive contractions assessed by the readiness potential. European Journal of Applied Physiology, 2006, 97, 521-526. | 1.2 | 32 |
| 179 | Reduced quantitative muscle function in tenascin-X deficient Ehlers-Danlos patients. Neuromuscular Disorders, 2007, 17, 597-602. | 0.3 | 32 |
| 180 | Autoantibodies to Cytosolic 5â€²-Nucleotidase 1A in Primary SjÃ¶grenâ€™s Syndrome and Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1200. | 2.2 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Panel-Based Exome Sequencing for Neuromuscular Disorders as a Diagnostic Service. Journal of Neuromuscular Diseases, 2019, 6, 241-258. | 1.1 | 32 |
| 182 | Proteasome-mediated degradation of integral inner nuclear membrane protein emerin in fibroblasts lacking A-type lamins. Biochemical and Biophysical Research Communications, 2006, 351, 1011-1017. | 1.0 | 31 |
| 183 | Health status in non-dystrophic myotonias: close relation with pain and fatigue. Journal of Neurology, 2009, 256, 939-947. | 1.8 | 31 |
| 184 | PGM1 deficiency: Substrate use during exercise and effect of treatment with galactose. Neuromuscular Disorders, 2017, 27, 370-376. | 0.3 | 31 |
| 185 | Llama-derived phage display antibodies in the dissection of the human disease oculopharyngeal muscular dystrophy. Journal of Immunological Methods, 2003, 279, 149-161. | 0.6 | 30 |
| 186 | Eosinophilic fasciitis in a child mimicking a myopathy. Neuromuscular Disorders, 2006, 16, 144-148. | 0.3 | 30 |
| 187 | Recurrent neuropathy associated with Ehlersâ€“Danlos syndrome. Journal of Neurology, 2006, 253, 670-671. | 1.8 | 30 |
| 188 | Strength training and aerobic exercise training for muscle disease. , 2010, , CD003907. | | 30 |
| 189 | Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study. Muscle and Nerve, 2015, 52, 534-539. | 1.0 | 30 |
| 190 | Genetic defects in the hexosamine and sialic acid biosynthesis pathway. Biochimica Et Biophysica Acta - General Subjects, 2016, 1860, 1640-1654. | 1.1 | 30 |
| 191 | Early onset as a marker for disease severity in facioscapulohumeral muscular dystrophy. Neurology, 2019, 92, e378-e385. | 1.5 | 30 |
| 192 | The Effect of Coenzyme Q10 Therapy in Parkinson Disease Could Be Symptomatic. Archives of Neurology, 2003, 60, 1170. | 4.9 | 30 |
| 193 | A new phenotype of autosomal dominant nemaline myopathy. Neuromuscular Disorders, 2002, 12, 13-18. | 0.3 | 29 |
| 194 | Statin-disclosed acid maltase deficiency. Journal of Internal Medicine, 2005, 258, 196-197. | 2.7 | 29 |
| 195 | BSCL2 mutations in two Dutch families with overlapping Silver syndrome-distal hereditary motor neuropathy. Neuromuscular Disorders, 2006, 16, 122-125. | 0.3 | 29 |
| 196 | Dysphagia is present but mild in myotonic dystrophy type 2. Neuromuscular Disorders, 2009, 19, 196-198. | 0.3 | 29 |
| 197 | Disease impact in chronic progressive external ophthalmoplegia: More than meets the eye. Neuromuscular Disorders, 2011, 21, 272-278. | 0.3 | 29 |
| 198 | SERCA1 protein expression in muscle of patients with Brody disease and Brody syndrome and in cultured human muscle fibers. Molecular Genetics and Metabolism, 2013, 110, 162-169. | 0.5 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | Reference values of maximum performance tests of speech production. International Journal of Speech-Language Pathology, 2019, 21, 56-64. | 0.6 | 29 |
| 200 | Employment status of patients with neuromuscular diseases in relation to personal factors, fatigue and health status: A secondary analysis. Journal of Rehabilitation Medicine, 2010, 42, 60-65. | 0.8 | 28 |
| 201 | Muscle characteristics and altered myofascial force transmission in tenascin-X-deficient mice, a mouse model of Ehlers-Danlos syndrome. Journal of Applied Physiology, 2010, 109, 986-995. | 1.2 | 28 |
| 202 | High Frequency of Neuropathic Pain in Ehlers-Danlos Syndrome: An Association with Axonal Polyneuropathy and Compression Neuropathy?. Journal of Pain and Symptom Management, 2011, 41, e4-e6. | 0.6 | 28 |
| 203 | Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study. BMC Neurology, 2019, 19, 224. | 0.8 | 28 |
| 204 | No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2006, 16, 766-769. | 0.3 | 27 |
| 205 | Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2. Human Molecular Genetics, 2018, 27, 3488-3497. | 1.4 | 27 |
| 206 | SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain. Journal of Medical Genetics, 2019, 56, 693-700. | 1.5 | 27 |
| 207 | Frequent occurrence of anti-tRNAHis autoantibodies that recognize a conformational epitope in sera of patients with myositis. Arthritis and Rheumatism, 1998, 41, 1428-1437. | 6.7 | 26 |
| 208 | Molecular Analysis of Myophosphorylase Deficiency in Dutch Patients with McArdle's Disease. Annals of Human Genetics, 2004, 68, 17-22. | 0.3 | 26 |
| 209 | High disease impact of myotonic dystrophy type 2 on physical and mental functioning. Journal of Neurology, 2011, 258, 1820-1826. | 1.8 | 26 |
| 210 | Mild Muscular Features in Tenascin-X Knockout Mice, A Model of Ehlersâ€“Danlos Syndrome. Connective Tissue Research, 2011, 52, 422-432. | 1.1 | 26 |
| 211 | Paediatric cerebrotendinous xanthomatosis. Journal of Inherited Metabolic Disease, 1992, 15, 374-376. | 1.7 | 25 |
| 212 | Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene. Human Mutation, 2003, 21, 553-553. | 1.1 | 25 |
| 213 | The relation between daytime sleepiness, fatigue, and reduced motivation in patients with adult onset myotonic dystrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2003, 74, 138-139. | 0.9 | 25 |
| 214 | Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetition. BMJ: British Medical Journal, 2004, 329, 1464-1467. | 2.4 | 25 |
| 215 | Muscle 3243Aâ†'G mutation load and capacity of the mitochondrial energyâ€generating system. Annals of Neurology, 2008, 63, 473-481. | 2.8 | 25 |
| 216 | Symptomatic lipid storage in carriers for the PNPLA2 gene. European Journal of Human Genetics, 2013, 21, 807-815. | 1.4 | 25 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | Shared medical appointments improve QOL in neuromuscular patients. Neurology, 2014, 83, 240-246. | 1.5 | 25 |
| 218 | Phenotypeâ€genotype relations in facioscapulohumeral muscular dystrophy type 1. Clinical Genetics, 2018, 94, 521-527. | 1.0 | 25 |
| 219 | Effects of weakness of orofacial muscles on swallowing and communication in FSHD. Neurology, 2019, 92, e957-e963. | 1.5 | 25 |
| 220 | Correlation Between Quantitative MRI and Muscle Histopathology in Muscle Biopsies from Healthy Controls and Patients with IBM, FSHD and OPMD. Journal of Neuromuscular Diseases, 2020, 7, 495-504. | 1.1 | 25 |
| 221 | KBTBD13 is an actin-binding protein that modulates muscle kinetics. Journal of Clinical Investigation, 2020, 130, 754-767. | 3.9 | 25 |
| 222 | Classification of employment factors according to the International Classification of Functioning, Disability and Health in patients with neuromuscular diseases: A systematic review. Disability and Rehabilitation, 2009, 31, 2150-2163. | 0.9 | 24 |
| 223 | Feverâ€induced recurrent rhabdomyolysis due to a novel mutation in the ryanodine receptor type 1 gene. Internal Medicine Journal, 2014, 44, 819-820. | 0.5 | 24 |
| 224 | FSHD type 2 and Bosma arhinia microphthalmia syndrome. Neurology, 2018, 91, e562-e570. | 1.5 | 24 |
| 225 | MRI-Guided Biopsy as a Tool for Diagnosis and Research of Muscle Disorders. Journal of Neuromuscular Diseases, 2018, 5, 315-319. | 1.1 | 24 |
| 226 | Skeletal muscle of mice with a mutation in slow Î±-tropomyosin is weaker at lower lengths. Neuromuscular Disorders, 2002, 12, 952-957. | 0.3 | 23 |
| 227 | Concomitant dermatomyositis and myasthenia gravis presenting with respiratory insufficiency. Muscle and Nerve, 2002, 25, 293-296. | 1.0 | 23 |
| 228 | Comparison of CMT1A and CMT2: similarities and differences. Journal of Neurology, 2006, 253, 1572-1580. | 1.8 | 23 |
| 229 | Skeletal muscle involvement in myotonic dystrophy type 2. A comparative muscle ultrasound study. Neuromuscular Disorders, 2012, 22, 492-499. | 0.3 | 23 |
| 230 | Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy. Clinical Biomechanics, 2014, 29, 855-860. | 0.5 | 23 |
| 231 | Double SMCHD1 variants in FSHD2: the synergistic effect of two SMCHD1 variants on D4Z4 hypomethylation and disease penetrance in FSHD2. European Journal of Human Genetics, 2016, 24, 78-85. | 1.4 | 23 |
| 232 | Affective symptoms and apathy in myotonic dystrophy type 1 a systematic review and meta-analysis. Journal of Affective Disorders, 2019, 250, 260-269. | 2.0 | 23 |
| 233 | Self-management program improves participation in patients with neuromuscular disease. Neurology, 2019, 93, e1720-e1731. | 1.5 | 23 |
| 234 | Structural white matter networks in myotonic dystrophy type 1. NeuroImage: Clinical, 2019, 21, 101615. | 1.4 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Muscle ultrasound is a responsive biomarker in facioscapulohumeral dystrophy. Neurology, 2020, 94, e1488-e1494. | 1.5 | 23 |
| 236 | Neuromuscular features in Marfan syndrome. Clinical Genetics, 2009, 76, 25-37. | 1.0 | 22 |
| 237 | Isolated eyelid closure myotonia in two families with sodium channel myotonia. Neurogenetics, 2010, 11, 257-260. | 0.7 | 22 |
| 238 | Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2. European Journal of Human Genetics, 2018, 26, 94-106. | 1.4 | 22 |
| 239 | Clinical, morphological and genetic characterization of Brody disease: an international study of 40 patients. Brain, 2020, 143, 452-466. | 3.7 | 22 |
| 240 | Overweight Is an Independent Risk Factor for Reduced Lung Volumes in Myotonic Dystrophy Type 1. PLoS ONE, 2016, 11, e0152344. | 1.1 | 22 |
| 241 | Sensorineural Hearing Impairment in Patients with Pmp22 Duplication, Deletion, and Frameshift Mutations. Otology and Neurotology, 2005, 26, 405-414. | 0.7 | 21 |
| 242 | Early diagnosis of ALS: The search for signs of denervation in clinically normal muscles. Journal of the Neurological Sciences, 2007, 263, 154-157. | 0.3 | 21 |
| 243 | Contribution of central and peripheral factors to residual fatigue in Guillainâ€“BarrÃ© syndrome. Muscle and Nerve, 2007, 36, 93-99. | 1.0 | 21 |
| 244 | Cell Membrane Integrity in Myotonic Dystrophy Type 1: Implications for Therapy. PLoS ONE, 2015, 10, e0121556. | 1.1 | 21 |
| 245 | Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843. | 1.0 | 21 |
| 246 | Lifetime endogenous estrogen exposure and disease severity in female patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2018, 28, 508-511. | 0.3 | 21 |
| 247 | Facioscapulohumeral Dystrophy in Childhood: A Nationwide Natural History Study. Annals of Neurology, 2018, 84, 627-637. | 2.8 | 21 |
| 248 | Human brain pathology in myotonic dystrophy type 1: A systematic review. Neuropathology, 2021, 41, 3-20. | 0.7 | 21 |
| 249 | <title>Validation of measurement protocols to assess oxygen consumption and blood flow in the human forearm by near-infrared spectroscopy</title>. , 1998, 3194, 133. | | 20 |
| 250 | 225th ENMC international workshop:. Neuromuscular Disorders, 2017, 27, 782-790. | 0.3 | 20 |
| 251 | Functional impairments, fatigue and quality of life in RYR1-related myopathies: A questionnaire study. Neuromuscular Disorders, 2019, 29, 30-38. | 0.3 | 20 |
| 252 | Phase 1 clinical trial of losmapimod in facioscapulohumeral dystrophy: Safety, tolerability, pharmacokinetics, and target engagement. British Journal of Clinical Pharmacology, 2021, 87, 4658-4669. | 1.1 | 20 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Involuntary painful muscle contractions in Satoyoshi syndrome: A surface electromyographic study. Movement Disorders, 2006, 21, 2015-2018. | 2.2 | 19 |
| 254 | Falls and resulting fractures in Myotonic Dystrophy: Results from a multinational retrospective survey. Neuromuscular Disorders, 2018, 28, 229-235. | 0.3 | 19 |
| 255 | Qualitative and Quantitative Aspects of Pain in Patients With Myotonic Dystrophy Type 2. Journal of Pain, 2018, 19, 920-930. | 0.7 | 19 |
| 256 | Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease. Orphanet Journal of Rare Diseases, 2018, 13, 155. | 1.2 | 19 |
| 257 | Serologie HLA typing in cryptogenic Lennox-Gastaut syndrome. Epilepsy Research, 1994, 17, 43-47. | 0.8 | 18 |
| 258 | A double missense mutation in the ATM gene of a Dutch family with ataxia telangiectasia. Human Genetics, 1998, 102, 187-191. | 1.8 | 18 |
| 259 | Guillainâ€“BarrÃ© syndrome as presenting feature in a patient with lupus nephritis, with complete resolution after cyclophosphamide treatment. Nephrology Dialysis Transplantation, 2001, 16, 840-842. | 0.4 | 18 |
| 260 | Proteomics and neuromuscular diseases: theoretical concept and first results. Annals of Clinical Biochemistry, 2003, 40, 9-15. | 0.8 | 18 |
| 261 | Na+-K+-ATPase is not involved in the warming-up phenomenon in generalized myotonia. Muscle and Nerve, 2006, 33, 514-523. | 1.0 | 18 |
| 262 | Development of a tool to guide referral of patients with neuromuscular disorders to allied health services. Part one. Disability and Rehabilitation, 2008, 30, 855-862. | 0.9 | 18 |
| 263 | Increased plasma amyloid-Î²42 protein in sporadic inclusion body myositis. Acta Neuropathologica, 2009, 118, 429-431. | 3.9 | 18 |
| 264 | Child Neurology: Differential diagnosis of a low CSF glucose in children and young adults. Neurology, 2013, 81, e178-81. | 1.5 | 18 |
| 265 | N-of-1 Trials: Evidence-Based Clinical Care or Medical Research that Requires IRB Approval? A Practical Flowchart Based on an Ethical Framework. Healthcare (Switzerland), 2020, 8, 49. | 1.0 | 18 |
| 266 | Electrocardiographic predictors of infrahissian conduction disturbances in myotonic dystrophy type 1. Europace, 2021, 23, 298-304. | 0.7 | 18 |
| 267 | Chromosome 10q-linked FSHD identifies DUX4 as principal disease gene. Journal of Medical Genetics, 2022, 59, 180-188. | 1.5 | 18 |
| 268 | High prevalence of incomplete right bundle branch block in facioscapulohumeral muscular dystrophy without cardiac symptoms. Functional Neurology, 2014, 29, 159-65. | 1.3 | 18 |
| 269 | Muscle Uridine Diphosphate-Hexosamines Do Not Decrease Despite Correction of Hyperglycemia-Induced Insulin Resistance in Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 5179-5184. | 1.8 | 17 |
| 270 | Muscle slowness in a family with nemaline myopathy. Neuromuscular Disorders, 2006, 16, 477-480. | 0.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Sleep disturbances in chronic progressive external ophthalmoplegia. European Journal of Neurology, 2012, 19, 176-178. | 1.7 | 17 |
| 272 | Combined N-of-1 trials to investigate mexiletine in non-dystrophic myotonia using a Bayesian approach; study rationale and protocol. BMC Neurology, 2015, 15, 43. | 0.8 | 17 |
| 273 | The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands. Neuromuscular Disorders, 2016, 26, 447-452. | 0.3 | 17 |
| 274 | Involvement of pelvic girdle and proximal leg muscles in early oculopharyngeal muscular dystrophy. Neuromuscular Disorders, 2017, 27, 1099-1105. | 0.3 | 17 |
| 275 | Insulin Signaling as a Key Moderator in Myotonic Dystrophy Type 1. Frontiers in Neurology, 2019, 10, 1229. | 1.1 | 17 |
| 276 | Short fatigue questionnaire: Screening for severe fatigue.. Journal of Psychosomatic Research, 2020, 137, 110229. | 1.2 | 17 |
| 277 | White matter abnormalities in congenital muscular dystrophy. Journal of the Neurological Sciences, 1995, 129, 162-169. | 0.3 | 16 |
| 278 | Nature and frequency of respiratory involvement in chronic progressive external ophthalmoplegia. Journal of Neurology, 2011, 258, 2020-2025. | 1.8 | 16 |
| 279 | Autoantibody testing in idiopathic inflammatory myopathies. Practical Neurology, 2019, 19, 284-294. | 0.5 | 16 |
| 280 | Deep phenotyping of facioscapulohumeral muscular dystrophy type 2 by magnetic resonance imaging. European Journal of Neurology, 2020, 27, 2604-2615. | 1.7 | 16 |
| 281 | Congenital fibre type disproportion a time-locked diagnosis: A clinical and morphological follow-up study. Clinical Neurology and Neurosurgery, 2000, 102, 97-101. | 0.6 | 15 |
| 282 | Diagnosis and Differential Diagnosis of Muscle Cramps: A Clinical Approach. Journal of Clinical Neuromuscular Disease, 2002, 4, 89-94. | 0.3 | 15 |
| 283 | Nuclear entrapment and extracellular depletion of PCOLCE is associated with muscle degeneration in oculopharyngeal muscular dystrophy. BMC Neurology, 2013, 13, 70. | 0.8 | 15 |
| 284 | How Persons with a Neuromuscular Disease Perceive Employment Participation: A Qualitative Study. Journal of Occupational Rehabilitation, 2014, 24, 52-67. | 1.2 | 15 |
| 285 | Effectiveness and cost-effectiveness of a self-management group program to improve social participation in patients with neuromuscular disease and chronic fatigue: protocol of the Energetic study. BMC Neurology, 2015, 15, 58. | 0.8 | 15 |
| 286 | Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). BMC Neurology, 2016, 16, 138. | 0.8 | 15 |
| 287 | The Dutch patients' perspective on oculopharyngeal muscular dystrophy: A questionnaire study on fatigue, pain and impairments. Neuromuscular Disorders, 2016, 26, 221-226. | 0.3 | 15 |
| 288 | Electrical impedance myography in facioscapulohumeral muscular dystrophy: A 1â€year followâ€up study. Muscle and Nerve, 2018, 58, 213-218. | 1.0 | 15 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Continued misuse of orphan drug legislation: a life-threatening risk for mexiletine. European Heart Journal, 2020, 41, 614-617. | 1.0 | 15 |
| 290 | Nijmegen Breakage Syndrome: A Neuropathological Study. Neuropediatrics, 2003, 34, 189-193. | 0.3 | 14 |
| 291 | A case of neuromuscular mimicry. Neuromuscular Disorders, 2006, 16, 510-513. | 0.3 | 14 |
| 292 | Development of a tool to guide referral of patients with neuromuscular disorders to allied health services. Part two. Disability and Rehabilitation, 2008, 30, 863-870. | 0.9 | 14 |
| 293 | Neuromuscular properties of the thigh muscles in patients with ehlersâ€“danlos syndrome. Muscle and Nerve, 2013, 47, 96-104. | 1.0 | 14 |
| 294 | Respiratory function in facioscapulohumeral muscular dystrophy 1. Neuromuscular Disorders, 2017, 27, 526-530. | 0.3 | 14 |
| 295 | Ophthalmological findings in facioscapulohumeral dystrophy. Brain Communications, 2019, 1, fcz023. | 1.5 | 14 |
| 296 | Quantitative nearâ€infrared spectroscopy discriminates between mitochondrial myopathies and normal muscle. Annals of Neurology, 1999, 46, 667-670. | 2.8 | 14 |
| 297 | Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers. Scientific Reports, 2022, 12, 1426. | 1.6 | 14 |
| 298 | Light chain ratios and concentrations of serum immunoglobulins in children with epilepsy. Epilepsy Research, 1992, 13, 255-260. | 0.8 | 13 |
| 299 | Warm-up phenomenon in myotonia associated with the V445M sodium channel mutation. Journal of Neurology, 2007, 254, 257-258. | 1.8 | 13 |
| 300 | Implementation of multidisciplinary advice to allied health care professionals regarding the management of their patients with neuromuscular diseases. Disability and Rehabilitation, 2011, 33, 787-795. | 0.9 | 13 |
| 301 | 184th ENMC international workshop: Pain and fatigue in neuromuscular disorders. Neuromuscular Disorders, 2013, 23, 1028-1032. | 0.3 | 13 |
| 302 | Characterizing the face in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2021, 268, 1342-1350. | 1.8 | 13 |
| 303 | Rasch analysis to evaluate the motor function measure for patients with facioscapulohumeral muscular dystrophy. International Journal of Rehabilitation Research, 2021, 44, 38-44. | 0.7 | 13 |
| 304 | Enhancement of central nervous system remyelination in immune and non-immune experimental models of demyelination. Multiple Sclerosis Journal, 1997, 3, 76-79. | 1.4 | 12 |
| 305 | Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy. Journal of Neurology, 2000, 247, 882-884. | 1.8 | 12 |
| 306 | Proteomics Approaches to Study Genetic and Metabolic Disorders. Journal of Proteome Research, 2007, 6, 506-512. | 1.8 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Optimizing referral of patients with neuromuscular disorders to allied health care. European Journal of Neurology, 2009, 16, 562-568. | 1.7 | 12 |
| 308 | Screening for antecedent Campylobacter jejuni infections and antiâ€ganglioside antibodies in idiopathic neuralgic amyotrophy. Journal of the Peripheral Nervous System, 2011, 16, 153-156. | 1.4 | 12 |
| 309 | Speech Pathology Interventions in Patients with Neuromuscular Diseases: A Systematic Review. Folia Phoniatrica Et Logopaedica, 2011, 63, 15-20. | 0.5 | 12 |
| 310 | Determining the role of sarcomeric proteins in facioscapulohumeral muscular dystrophy: a study protocol. BMC Neurology, 2013, 13, 144. | 0.8 | 12 |
| 311 | The individualized neuromuscular quality of life questionnaire: Cultural translation and psychometric validation for the Dutch population. Muscle and Nerve, 2015, 51, 496-500. | 1.0 | 12 |
| 312 | Diagnostics of short tandem repeat expansion variants using massively parallel sequencing and componential tools. European Journal of Human Genetics, 2019, 27, 400-407. | 1.4 | 12 |
| 313 | Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 7, 1-12. | 1.1 | 12 |
| 314 | Natural history, outcome measures and trial readiness in LAMA2-related muscular dystrophy and SELENON-related myopathy in children and adults: protocol of the LAST STRONG study. BMC Neurology, 2021, 21, 313. | 0.8 | 12 |
| 315 | Muscle function in a patient with Brody's disease. Muscle and Nerve, 1999, 22, 704-711. | 1.0 | 11 |
| 316 | The Regulation of Fine Movements in Patients with Charcot Marie Tooth, Type la: Some Ideas about Continuous Adaptation. Motor Control, 2001, 5, 200-214. | 0.3 | 11 |
| 317 | Influence of Relatives on Fatigue Experienced by Patients with Facioscapulohumeral Dystrophy, Myotonic Dystrophy and HMSN-I. European Neurology, 2006, 56, 24-30. | 0.6 | 11 |
| 318 | The wrong end of the telescope: neuromuscular mimics of movement disorders (and vice versa). Practical Neurology, 2016, 16, 264-269. | 0.5 | 11 |
| 319 | Hearing impairment in patients with myotonic dystrophy type 2. Neurology, 2018, 90, e615-e622. | 1.5 | 11 |
| 320 | Specific muscle strength is reduced in facioscapulohumeral dystrophy: An MRI based musculoskeletal analysis. Neuromuscular Disorders, 2018, 28, 238-245. | 0.3 | 11 |
| 321 | Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review. Patient, 2019, 12, 365-373. | 1.1 | 11 |
| 322 | Quantitative Muscle MRI Depicts Increased Muscle Mass after a Behavioral Change in Myotonic Dystrophy Type 1. Radiology, 2020, 297, 132-142. | 3.6 | 11 |
| 323 | Systemic cell therapy for muscular dystrophies. Stem Cell Reviews and Reports, 2021, 17, 878-899. | 1.7 | 11 |
| 324 | Longitudinal Assessment of Strength, Functional Capacity, Oropharyngeal Function, and Quality of Life in Oculopharyngeal Muscular Dystrophy. Neurology, 2021, 97, e1475-e1483. | 1.5 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | Familial adult-onset muscular dystrophy with leukoencephalopathy. Annals of Neurology, 1992, 32, 577-580. | 2.8 | 10 |
| 326 | The effect of dantrolene sodium in Very Long Chain Acyl-CoA Dehydrogenase Deficiency. Neuromuscular Disorders, 2005, 15, 844-846. | 0.3 | 10 |
| 327 | Radicular dysfunction due to spinal deformities in Marfan syndrome at older age: Three case reports. European Journal of Medical Genetics, 2010, 53, 35-39. | 0.7 | 10 |
| 328 | Effects of shared medical appointments on quality of life and cost-effectiveness for patients with a chronic neuromuscular disease. Study protocol of a randomized controlled trial. BMC Neurology, 2011, 11, 106. | 0.8 | 10 |
| 329 | Integrating clinical and genetic observations in facioscapulohumeral muscular dystrophy. Current Opinion in Neurology, 2016, 29, 606-613. | 1.8 | 10 |
| 330 | The yield of diagnostic work-up of patients presenting with myalgia, exercise intolerance, or fatigue. Neuromuscular Disorders, 2017, 27, 243-250. | 0.3 | 10 |
| 331 | High incidence of falls in patients with myotonic dystrophy type 1 and 2: A prospective study. Neuromuscular Disorders, 2019, 29, 758-765. | 0.3 | 10 |
| 332 | Altered sensorimotor representations after recovery from peripheral nerve damage in neuralgic amyotrophy. Cortex, 2020, 127, 180-190. | 1.1 | 10 |
| 333 | Associations Between Variant Repeat Interruptions and Clinical Outcomes in Myotonic Dystrophy Type 1. Neurology: Genetics, 2021, 7, e572. | 0.9 | 10 |
| 334 | Cerebrospinal fluid examinations in cryptogenic West and Lennox-Gastaut syndrome before and after intravenous immunoglobulin administration. Epilepsy Research, 1994, 18, 139-147. | 0.8 | 9 |
| 335 | Quadriceps weakness in a family with nemaline myopathy: influence of knee angle. Clinical Science, 2003, 105, 585-589. | 1.8 | 9 |
| 336 | Warming up improves speech production in patients with adult onset myotonic dystrophy. Journal of Communication Disorders, 2007, 40, 185-195. | 0.8 | 9 |
| 337 | The Evidence for Occupational Therapy for Adults with Neuromuscular Diseases: A Systematic Review. OTJR Occupation, Participation and Health, 2008, 28, 12-18. | 0.4 | 9 |
| 338 | TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. Acta Neuropathologica, 2010, 120, 825-826. | 3.9 | 9 |
| 339 | Primary Cataract as a Key to Recognition of Myotonic Dystrophy Type 1. European Journal of Ophthalmology, 2015, 25, e46-e49. | 0.7 | 9 |
| 340 | Myotonic discharges discriminate chloride from sodium muscle channelopathies. Neuromuscular Disorders, 2015, 25, 73-80. | 0.3 | 9 |
| 341 | NA-CONTROL: a study protocol for a randomised controlled trial to compare specific outpatient rehabilitation that targets cerebral mechanisms through relearning motor control and uses self-management strategies to improve functional capability of the upper extremity, to usual care in patients with neuralgic amyotrophy. Trials, 2019, 20, 482. | 0.7 | 9 |
| 342 | Age-Associated Salivary MicroRNA Biomarkers for Oculopharyngeal Muscular Dystrophy. International Journal of Molecular Sciences, 2020, 21, 6059. | 1.8 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Reduced specific force in patients with mild and severe facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2021, 63, 60-67. | 1.0 | 9 |
| 344 | Quantitative Measurement of Oxygen Consumption and Forearm Blood Flow in Patients with Mitochondrial Myopathies. Advances in Experimental Medicine and Biology, 1999, 471, 313-319. | 0.8 | 9 |
| 345 | Postural changes, dysphagia, and systemic sclerosis. Annals of the Rheumatic Diseases, 1998, 57, 331-338. | 0.5 | 8 |
| 346 | Upregulation of Ca<sup>2+</sup>removal in human skeletal muscle: a possible role for Ca<sup>2+</sup>-dependent priming of mitochondrial ATP synthesis. American Journal of Physiology - Cell Physiology, 2003, 285, C1263-C1269. | 2.1 | 8 |
| 347 | Gait propulsion in patients with facioscapulohumeral muscular dystrophy and ankle plantarflexor weakness. Gait and Posture, 2015, 41, 476-481. | 0.6 | 8 |
| 348 | A 22-year follow-up reveals a variable disease severity in early-onset facioscapulohumeral dystrophy. European Journal of Paediatric Neurology, 2018, 22, 782-785. | 0.7 | 8 |
| 349 | Swallowing, Chewing and Speaking: Frequently Impaired in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2020, 7, 483-494. | 1.1 | 8 |
| 350 | Preserved single muscle fiber specific force in facioscapulohumeral muscular dystrophy. Neurology, 2020, 94, e1157-e1170. | 1.5 | 8 |
| 351 | The facioscapulohumeral muscular dystrophy Raschâ€built overall disability scale (FSHDâ€RODS). European Journal of Neurology, 2021, 28, 2339-2348. | 1.7 | 8 |
| 352 | The neuromuscular and multisystem features of RYR1-related malignant hyperthermia and rhabdomyolysis. Medicine (United States), 2021, 100, e26999. | 0.4 | 8 |
| 353 | High-resolution breakpoint junction mapping of proximally extended D4Z4 deletions in FSHD1 reveals evidence for a founder effect. Human Molecular Genetics, 2022, 31, 748-760. | 1.4 | 8 |
| 354 | Are muscle cramps in Isaacs' syndrome triggered by human immunoglobulin?. Journal of Neurology, Neurosurgery and Psychiatry, 1995, 58, 393-393. | 0.9 | 7 |
| 355 | Maintaining Constant Voluntary Force in Generalized Myotonia Despite Muscle Membrane Disturbances: Insights from a High-Density Surface EMG Study. Journal of Clinical Neurophysiology, 2004, 21, 114-123. | 0.9 | 7 |
| 356 | Fast Responses to Stepping on an Unexpected Surface Height Depend on Intact Large-Diameter Nerve Fibers: A Study on Charcotâ€“Marieâ€“Tooth Type 1A Disease. Journal of Neurophysiology, 2009, 102, 1684-1698. | 0.9 | 7 |
| 357 | Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry the common European founder haplotype. European Journal of Human Genetics, 2011, 19, 567-570. | 1.4 | 7 |
| 358 | Cost-effectiveness of shared medical appointments for neuromuscular patients. Neurology, 2015, 85, 619-625. | 1.5 | 7 |
| 359 | Clinical practice considerations in facioscapulohumeral muscular dystrophy Sydney, Australia, 21 September 2015. Neuromuscular Disorders, 2016, 26, 462-471. | 0.3 | 7 |
| 360 | The Position of Neuromuscular Patients in Shared Decision Making. Report from the 235th ENMC Workshop: Milan, Italy, January 19-20, 2018. Journal of Neuromuscular Diseases, 2019, 6, 161-172. | 1.1 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Clinical, genetic, and histological features of centronuclear myopathy in the Netherlands. Clinical Genetics, 2021, 100, 692-702. | 1.0 | 7 |
| 362 | N-of-1 Trials in Neurology. Neurology, 2022, 98, . | 1.5 | 7 |
| 363 | Natural History of Facioscapulohumeral Dystrophy in Children. Neurology, 2021, 97, e2103-e2113. | 1.5 | 7 |
| 364 | Respiratory muscle function in patients with nemaline myopathy. Neuromuscular Disorders, 2022, 32, 654-663. | 0.3 | 7 |
| 365 | Tubular Aggregates. Archives of Neurology, 1999, 56, 1410. | 4.9 | 6 |
| 366 | Diagnostic yield of muscle fibre conduction velocity in myopathies. Journal of the Neurological Sciences, 2011, 309, 40-44. | 0.3 | 6 |
| 367 | Dynamic stability during level walking and obstacle crossing in persons with facioscapulohumeral muscular dystrophy. Gait and Posture, 2015, 42, 295-300. | 0.6 | 6 |
| 368 | Characterization of sarcoplasmic reticulum Ca2+ ATPase pumps in muscle of patients with myotonic dystrophy and with hypothyroid myopathy. Neuromuscular Disorders, 2016, 26, 378-385. | 0.3 | 6 |
| 369 | New Insights in Adherence and Survival in Myotonic Dystrophy Patients Using Home Mechanical Ventilation. Respiration, 2021, 100, 154-163. | 1.2 | 6 |
| 370 | Profiling Serum Antibodies Against Muscle Antigens in Facioscapulohumeral Muscular Dystrophy Finds No Disease-Specific Autoantibodies. Journal of Neuromuscular Diseases, 2021, 8, 801-814. | 1.1 | 6 |
| 371 | Near-infrared spectroscopy in chronic progressive external ophthalmoplegia: Adipose tissue thickness confounds decreased muscle oxygen consumption. Annals of Neurology, 2002, 51, 272-273. | 2.8 | 5 |
| 372 | Persistent increased risk for thymoma in myasthenia gravis associated with myositis. Muscle and Nerve, 2006, 34, 251-252. | 1.0 | 5 |
| 373 | Ambulatory disabilities and the use of walking aids in patients with Hereditary Motor and Sensory Neuropathy type I (HMSN I). Disability and Rehabilitation: Assistive Technology, 2007, 2, 35-41. | 1.3 | 5 |
| 374 | Caffeine and Muscle Cramps: A Stimulating Connection. American Journal of Medicine, 2007, 120, e1-e2. | 0.6 | 5 |
| 375 | Chronic progressive external ophthalmoplegia caused by an m.4267A > G mutation in the mitochondrial tRNAIle. Journal of Neurology, 2007, 254, 1614-1615. | 1.8 | 5 |
| 376 | The phenotype of the Gly94fsX222 PMP22 insertion. Journal of the Peripheral Nervous System, 2011, 16, 113-118. | 1.4 | 5 |
| 377 | No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome. Neuromuscular Disorders, 2016, 26, 370-373. | 0.3 | 5 |
| 378 | Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. Journal of Rheumatology, 2018, 45, 441.1-442. | 1.0 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | Repeatability and reliability of muscle relaxation properties induced by motor cortical stimulation. Journal of Applied Physiology, 2018, 124, 1597-1604. | 1.2 | 5 |
| 380 | Noninvasive Home Mechanical Ventilation in Adult Myotonic Dystrophy Type 1: A Systematic Review. Respiration, 2021, 100, 816-825. | 1.2 | 5 |
| 381 | Respiratory muscle imaging by ultrasound and MRI in neuromuscular disorders. European Respiratory Journal, 2021, 58, 2100137. | 3.1 | 5 |
| 382 | The socioeconomic burden of facioscapulohumeral muscular dystrophy. Journal of Neurology, 2021, 268, 4778-4788. | 1.8 | 5 |
| 383 | Facioscapulohumeral muscular dystrophyâ€"Reproductive counseling, pregnancy, and delivery in a complex multigenetic disease. Clinical Genetics, 2022, 101, 149-160. | 1.0 | 5 |
| 384 | Scheie Syndrome Presenting as Myopathy. Neuropediatrics, 2001, 32, 93-96. | 0.3 | 4 |
| 385 | NIR spectroscopic measurement of local muscle metabolism during rhythmic, sustained, and intermittent handgrip exercise. , 2003, , . | | 4 |
| 386 | Auditory Processing in Patients With Charcot-Marie-Tooth Disease Type 1A. Otology and Neurotology, 2003, 24, 872-877. | 0.7 | 4 |
| 387 | Contractile properties of knee-extensors in one single family with nemaline myopathy: central and peripheral aspects of muscle activation. Clinical Physiology and Functional Imaging, 2007, 27, 217-224. | 0.5 | 4 |
| 388 | Computer-aided visualization of muscle weakness distribution. Journal of Neurology, 2008, 255, 1670-1678. | 1.8 | 4 |
| 389 | Problems of Adults with a Mitochondrial Disease â€“ The Patientsâ€™ Perspective: Focus on Loss. JIMD Reports, 2012, 6, 85-94. | 0.7 | 4 |
| 390 | Exploring Employment in Consultation Reports of Patients With Neuromuscular Diseases. Archives of Physical Medicine and Rehabilitation, 2012, 93, 2276-2280. | 0.5 | 4 |
| 391 | The European NeuroMuscular Centre (ENMC): 20 years on â€¦. Neuromuscular Disorders, 2013, 23, 375-376. | 0.3 | 4 |
| 392 | LAMA2 mutations in adult-onset muscular dystrophy with leukoencephalopathy. Muscle and Nerve, 2014, 49, 616-617. | 1.0 | 4 |
| 393 | Both aerobic exercise training and cognitive behavior therapy reduce chronic fatigue in patients with facioscapulohumeral muscular dystrophy: A randomized controlled trial. Annals of Physical and Rehabilitation Medicine, 2014, 57, e96. | 1.1 | 4 |
| 394 | Clinical Functional Capacity Testing in Patients With Facioscapulohumeral Muscular Dystrophy: Construct Validity and Interrater Reliability of Antigravity Tests. Archives of Physical Medicine and Rehabilitation, 2015, 96, 2201-2206. | 0.5 | 4 |
| 395 | Monitoring creatine and phosphocreatine by 13C MR spectroscopic imaging during and after 13C4 creatine loading: a feasibility study. Amino Acids, 2016, 48, 1857-1866. | 1.2 | 4 |
| 396 | Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida etÂal. Arthritis and Rheumatology, 2017, 69, 2248-2249. | 2.9 | 4 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | NEM6, KBTBD13-Related Congenital Myopathy: Myopathological Analysis in 18 Dutch Patients Reveals Ring Rods Fibers, Cores, Nuclear Clumps, and Granulo-Filamentous Protein Material. Journal of Neuropathology and Experimental Neurology, 2021, 80, 366-376. | 0.9 | 4 |
| 398 | Clinical Outcome Evaluations and CBT Response Prediction in Myotonic Dystrophy. Journal of Neuromuscular Diseases, 2021, 8, 1031-1046. | 1.1 | 4 |
| 399 | Serial Isoelectric Focusing as an Effective and Economic Way to Obtain Maximal Resolution and High-Throughput in 2D-Based Comparative Proteomics of Scarce Samples:Â Proof-of-Principle. Journal of Proteome Research, 2005, 4, 2364-2368. | 1.8 | 3 |
| 400 | Sensorimotor Axonal Polyneuropathy Without Hepatic Failure in Erythropoietic Protoporphyria. Journal of Clinical Neuromuscular Disease, 2009, 11, 72-76. | 0.3 | 3 |
| 401 | The neglected brain in myotonic dystrophy types 1 and 2. Neurology, 2010, 74, 1090-1091. | 1.5 | 3 |
| 402 | The astrologist's posture: a useful clinical observation. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 164-164. | 0.9 | 3 |
| 403 | Compound heterozygous mutations of the TNXB gene cause primary myopathy. Neuromuscular Disorders, 2014, 24, 88-89. | 0.3 | 3 |
| 404 | Characteristics and natural history of oculopharyngeal muscular dystrophy (OPMD): The study protocol of â€˜OPMD Forteâ€™. Neuromuscular Disorders, 2016, 26, S139-S140. | 0.3 | 3 |
| 405 | Cytokine genes as potential biomarkers for muscle weakness in OPMD. Human Molecular Genetics, 2016, 25, 4282-4287. | 1.4 | 3 |
| 406 | Bilateral Vestibulopathy Aggravates Balance and Gait Disturbances in Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis: A Case Report. Journal of Clinical Neuromuscular Disease, 2016, 18, 34-36. | 0.3 | 3 |
| 407 | Oculopharyngeal muscular dystrophy with frontotemporal dementia. European Geriatric Medicine, 2017, 8, 81-83. | 1.2 | 3 |
| 408 | Muscle fiber dysfunction contributes to weakness in inclusion body myositis. Neuromuscular Disorders, 2019, 29, 468-476. | 0.3 | 3 |
| 409 | Semiâ€automated Rasch analysis using inâ€plusâ€outâ€ofâ€questionnaire log likelihood. British Journal of Mathematical and Statistical Psychology, 2021, 74, 313-339. | 1.0 | 3 |
| 410 | Mixed methods evaluation of a self-management group programme for patients with neuromuscular disease and chronic fatigue. BMJ Open, 2021, 11, e048890. | 0.8 | 3 |
| 411 | Experiences of patients with facioscapulohumeral dystrophy with facial weakness: a qualitative study. Disability and Rehabilitation, 2022, 44, 6775-6782. | 0.9 | 3 |
| 412 | Neurological features of Noonan syndrome and related <scp>RASopathies</scp> : Pain and nerve enlargement characterized by nerve ultrasound. American Journal of Medical Genetics, Part A, 2022, , . | 0.7 | 3 |
| 413 | Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1). International Journal of Molecular Sciences, 2022, 23, 3081. | 1.8 | 3 |
| 414 | Halothane-induced Calcium Release in Cultured Human Skeletal Muscle Cells from a Family Susceptible to Malignant Hyperthermia with an Unidentified Mutation in Chromosome 19. Anesthesiology, 2002, 97, 272-274. | 1.3 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | Less is more: treatment of aggravating behaviour in myasthenia gravis patients with dysphagia. European Journal of Neurology, 2002, 9, 688-689. | 1.7 | 2 |
| 416 | G.P.15. Neuromuscular Disorders, 2014, 24, 798-799. | 0.3 | 2 |
| 417 | Effect of Suboptimal Sampling and Handling Conditions on Urinary Metabolic Profiles. Chromatographia, 2015, 78, 429-434. | 0.7 | 2 |
| 418 | Clinical phenotype and outcome of hepatitis E virus associated neuralgic amyotrophy; an international retrospective comparative cohort study. Journal of Hepatology, 2017, 66, S59. | 1.8 | 2 |
| 419 | Inclusion body myositis in patients with spinocerebellar ataxia types 3 and 6. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 876-878. | 0.9 | 2 |
| 420 | Antiâ€“Cytosolic 5â€²â€Nucleotidase 1A Autoantibodies Are Absent in Juvenile Dermatomyositis. Arthritis and Rheumatology, 2021, 73, 1329-1333. | 2.9 | 2 |
| 421 | Long-term follow-up of respiratory function in facioscapulohumeral muscular dystrophy. Journal of Neurology, 2022, 269, 3682-3689. | 1.8 | 2 |
| 422 | Visuomotor processing is altered after peripheral nerve damage in neuralgic amyotrophy. Brain Communications, 2022, 4, fcac034. | 1.5 | 2 |
| 423 | Development and validation of the patient-reported â€œFacial Function Scaleâ€• for facioscapulohumeral muscular dystrophy. Disability and Rehabilitation, 2023, 45, 1530-1535. | 0.9 | 2 |
| 424 | Reachable workspace analysis is a potential measurement for impairment of the upper extremity in neuralgic amyotrophy. Muscle and Nerve, 2022, 66, 282-288. | 1.0 | 2 |
| 425 | Can human polyclonal immunoglobulin raise the threshold for convulsions in rats?. Seizure: the Journal of the British Epilepsy Association, 1996, 5, 171-174. | 0.9 | 1 |
| 426 | Intravenous immunoglobulin preparation increases myoplasmic calcium concentration by activating the dihydropyridineâ€“ryanodine receptor complex. Journal of the Neurological Sciences, 1998, 156, 35-40. | 0.3 | 1 |
| 427 | Autoantibody Testing in the Evaluation of Idiopathic Inflammatory Myopathies. Journal of Clinical Neuromuscular Disease, 2000, 2, 1-2. | 0.3 | 1 |
| 428 | O.15 Mutations in the skeletal muscle ryanodine receptor (RYR1) gene presenting with exertional myalgia and rhabdomyolysis. Neuromuscular Disorders, 2011, 21, 748. | 0.3 | 1 |
| 429 | Severe Dejerineâ€Sottas disease with respiratory failure and dysmorphic features in association with a PMP22 point mutation and a 3q23 microdeletion. Journal of the Peripheral Nervous System, 2012, 17, 223-225. | 1.4 | 1 |
| 430 | IMPLICATIONS OF ANTI-CN1A SEROTYPE IN INCLUSION BODY MYOSITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.160-e1. | 0.9 | 1 |
| 431 | Adding quantitative muscle MRI to the FSHD clinical trial toolbox. Neuromuscular Disorders, 2017, 27, S122. | 0.3 | 1 |
| 432 | Evidence of ER stress and UPR activation in patients with Brody disease and Brody syndrome. Neuropathology and Applied Neurobiology, 2018, 44, 533-536. | 1.8 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | O.25Phase 1 clinical trial of losmapimod in FSHD: safety, tolerability and target engagement. Neuromuscular Disorders, 2019, 29, S123. | 0.3 | 1 |
| 434 | Scapular dyskinesis in myotonic dystrophy type 1: clinical characteristics and genetic investigations. Journal of Neurology, 2019, 266, 2987-2996. | 1.8 | 1 |
| 435 | Characterization of EEG-based functional brain networks in myotonic dystrophy type 1. Clinical Neurophysiology, 2020, 131, 1886-1895. | 0.7 | 1 |
| 436 | 248th ENMC International Workshop: Myotonic dystrophies: Molecular approaches for clinical purposes, framing a European molecular research network, Hoofddorp, the Netherlands, 11â€“13 October 2019. Neuromuscular Disorders, 2020, 30, 521-531. | 0.3 | 1 |
| 437 | N-of-1 trial of salbutamol in hyperkalaemic periodic paralysis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, jnnp-2021-326347. | 0.9 | 1 |
| 438 | Behavioural Impairment and Frontotemporal Dementia in Oculopharyngeal Muscular Dystrophy. Journal of Neuromuscular Diseases, 2021, , 1-7. | 1.1 | 1 |
| 439 | Exploring the influence of smoking and alcohol consumption on clinical severity in patients with facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2021, 31, 824-828. | 0.3 | 1 |
| 440 | Care for capabilities: Implementing the capability approach in rehabilitation of patients with neuromuscular diseases. Study protocol of the controlled before-after ReCap-NMD study. PLoS ONE, 2021, 16, e0261475. | 1.1 | 1 |
| 441 | Quantitative Muscle Analysis in Facioscapulohumeral Muscular Dystrophy Using <scp>Wholeâ€Body Fatâ€Referenced MRI</scp> : Protocol Development, Multicenter Feasibility, and Repeatability. Muscle and Nerve, 2022, , . | 1.0 | 1 |
| 442 | An evaluation of 24â€...h Holter monitoring in patients with myotonic dystrophy type 1. Europace, 0, , . | 0.7 | 1 |
| 443 | Polyclonal Ig: an immunopharmacon?. Trends in Immunology, 1994, 15, 341-342. | 7.5 | 0 |
| 444 | Disease Course of Charcot-Marie-Tooth Disease Type 2 and Comorbidityâ€”Reply. Archives of Neurology, 2004, 61, 1470. | 4.9 | 0 |
| 445 | Safety of the Posterior Approach to the Brachial Plexus. Anesthesia and Analgesia, 2006, 103, 1046. | 1.1 | 0 |
| 446 | G.P.7.13 Gene expression profiling in a skeletal muscle cell model of oculopharyngeal muscular dystrophy reveals an extracellular matrix defect. Neuromuscular Disorders, 2007, 17, 809. | 0.3 | 0 |
| 447 | G.P.10.13 Genotype-phenotype correlations for the skeletal muscle chloride- and sodium-channelopathies. Neuromuscular Disorders, 2007, 17, 821-822. | 0.3 | 0 |
| 448 | C.P.2.02 Neuromuscular involvement in Ehlers-Danlos syndrome. Neuromuscular Disorders, 2007, 17, 843-844. | 0.3 | 0 |
| 449 | G.P.14.13 Gastrointestinal symptoms in myotonic dystrophy type 2. Neuromuscular Disorders, 2007, 17, 857-858. | 0.3 | 0 |
| 450 | M.P.4.08 Are oxidative capacity and glycolysis affected in X-linked phosphorylase b kinase deficiency?. Neuromuscular Disorders, 2007, 17, 861. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Cervical myelopathy caused by retrograde intraneural dissection of anesthetic solution. Muscle and Nerve, 2008, 37, 546-547. | 1.0 | 0 |
| 452 | D.P.4.02 Dysphagia in Myotonic Dystrophy type 2. Neuromuscular Disorders, 2008, 18, 796-797. | 0.3 | 0 |
| 453 | 73 Problems of Children and Adolescents with a Mitochondrial Disease, Their Parents and Siblings. The Patients Perspective.. Pediatric Research, 2010, 68, 40-40. | 1.1 | 0 |
| 454 | O.12 A new member of the BTB/Kelch family of proteins is mutated in nemaline myopathy type 6 (NEM6). Neuromuscular Disorders, 2010, 20, 638. | 0.3 | 0 |
| 455 | P2.44 Accelerated skeletal muscle ageing is a molecular signature in OPMD. Neuromuscular Disorders, 2011, 21, 673. | 0.3 | 0 |
| 456 | Coffee and muscle cramps. Neuromuscular Disorders, 2011, 21, 832. | 0.3 | 0 |
| 457 | Dominant Mutations in KBTBD13, a Member of the BTB/Kelch Family, Cause Nemaline Myopathy with Cores. American Journal of Human Genetics, 2011, 88, 122. | 2.6 | 0 |
| 458 | C.P.3 Genetic and clinical heterogeneity of RYR1-related myopathies in a cohort of 60 Dutch families with identification of 40 novel mutations. Neuromuscular Disorders, 2012, 22, 841. | 0.3 | 0 |
| 459 | G.P.108 Sarcomeric dysfunction contributes to muscle weakness in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2012, 22, 900-901. | 0.3 | 0 |
| 460 | Exertional hyperckemia might be the first manifestation of a genetic disorder. Muscle and Nerve, 2013, 48, 461-462. | 1.0 | 0 |
| 461 | G.O.28. Neuromuscular Disorders, 2014, 24, 923-924. | 0.3 | 0 |
| 462 | G.P.131. Neuromuscular Disorders, 2014, 24, 840. | 0.3 | 0 |
| 463 | Histological abnormalities induced by the electromyography needle. Neuromuscular Disorders, 2014, 24, 77-78. | 0.3 | 0 |
| 464 | Muscle MRI correlates with histology and clinical features in patients with FSHD, OPMD and sIBM. Neuromuscular Disorders, 2015, 25, S295-S296. | 0.3 | 0 |
| 465 | Computerized quantification of facial weakness in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2015, 25, S214. | 0.3 | 0 |
| 466 | Overlap laminopathy with mild neurogenic atrophy and overt muscular dystrophy. Neuromuscular Disorders, 2015, 25, S279. | 0.3 | 0 |
| 467 | A2.4â€...Subcellular localisation of cytosolic 5â€™-nucleotidase 1A in cell lines and skeletal muscle: implications for inclusion body myositis. Annals of the Rheumatic Diseases, 2015, 74, A17.1-A17. | 0.5 | 0 |
| 468 | Disease modifying factors in facioscapulohumeral muscular dystrophy: Protocol of the FSHD-FOCUS study. Neuromuscular Disorders, 2015, 25, S214-S215. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | PGM1 deficiency â€“ A heterogeneous myopathy with opportunities for treatment. Neuromuscular Disorders, 2015, 25, S188-S189. | 0.3 | 0 |
| 470 | Why are FSHD muscles weak? A novel role for sarcomeric proteins. Neuromuscular Disorders, 2015, 25, S213. | 0.3 | 0 |
| 471 | Axial myopathy in a patient with a heterozygous MSTN mutation. Neuromuscular Disorders, 2015, 25, S216. | 0.3 | 0 |
| 472 | The energetic study: Effectiveness of a self-management group programme to improve social participation in patients with neuromuscular disease and chronic fatigue. Neuromuscular Disorders, 2016, 26, S147. | 0.3 | 0 |
| 473 | Contractile dysfunction in permeabilized muscle fibers of NEM6 patients with the Dutch founder mutation in KBTBD13. Neuromuscular Disorders, 2016, 26, S134. | 0.3 | 0 |
| 474 | Getting the picture of facioscapulohumeral muscular dystrophy: Muscle magnetic resonance imaging and ultrasound. Neuromuscular Disorders, 2016, 26, S101. | 0.3 | 0 |
| 475 | Implementation and process evaluation of the energetic study. Neuromuscular Disorders, 2016, 26, S147-S148. | 0.3 | 0 |
| 476 | Gene variants in SMCHD1 and DNMT3B modify the risk for FSHD. Neuromuscular Disorders, 2016, 26, S152. | 0.3 | 0 |
| 477 | Changes in sarcomeric contractile function influence force generation in facioscapulohumeral muscular dystrophy. Neuromuscular Disorders, 2016, 26, S167. | 0.3 | 0 |
| 478 | Respiratory pattern in a FSHD pediatric population. Respiratory Medicine, 2017, 126, 130-131. | 1.3 | 0 |
| 479 | Muscle fiber dysfunction contributes to clinical muscle weakness in inclusion body myositis. Neuromuscular Disorders, 2017, 27, S154. | 0.3 | 0 |
| 480 | The Brody disease cohort study: clarification of the phenotype. Neuromuscular Disorders, 2017, 27, S164. | 0.3 | 0 |
| 481 | Specific strength is reduced in facioscapulohumeral dystrophy muscles. An MRI-based musculoskeletal analysis. Neuromuscular Disorders, 2017, 27, S200. | 0.3 | 0 |
| 482 | Immunemediated necrotizing autoimmune myopathy: Dutch and Belgian experience. Neuromuscular Disorders, 2017, 27, S151. | 0.3 | 0 |
| 483 | Muscular fat fraction correlates with functionality in myotonic dystrophy type 1. Neuromuscular Disorders, 2017, 27, S180. | 0.3 | 0 |
| 484 | Retinal abnormalities in FSHD. Neuromuscular Disorders, 2017, 27, S201. | 0.3 | 0 |
| 485 | Slow relaxation kinetics of sarcomeres contribute to muscle slowness in NEM6 patients. Neuromuscular Disorders, 2017, 27, S230. | 0.3 | 0 |
| 486 | CONGENITAL MYOPATHIES: NEMALINE AND TITINOPATHIES. Neuromuscular Disorders, 2018, 28, S100-S101. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | NEW GENES, FUNCTIONS AND BIOMARKERS. Neuromuscular Disorders, 2018, 28, S31. | 0.3 | 0 |
| 488 | P.40Ophthalmological findings in facioscapulohumeral dystrophy. Neuromuscular Disorders, 2019, 29, S52-S53. | 0.3 | 0 |
| 489 | P.46Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, multi-center prospective study. Neuromuscular Disorders, 2019, 29, S54. | 0.3 | 0 |
| 490 | P.63Chronic progressive external ophthalmoplegia (CPEO) and CPEO-plus cohort of 54 patients from the Netherlands. Neuromuscular Disorders, 2019, 29, S59. | 0.3 | 0 |
| 491 | P.162Novel Kbtbd13R408C-knockin mouse model phenocopies NEM6 myopathy. Neuromuscular Disorders, 2019, 29, S95. | 0.3 | 0 |
| 492 | O.13Nemaline myopathy patients with mutations in KBTBD13 display a cardiac phenotype. Neuromuscular Disorders, 2019, 29, S118. | 0.3 | 0 |
| 493 | P.247Capturing disease progression in oculopharyngeal muscular dystrophy (OPMD). Neuromuscular Disorders, 2019, 29, S139. | 0.3 | 0 |
| 494 | P.306Multicentric MRI study in a cohort of FSHD2 patients: pattern definition and differences between FSHD1 and FSHD2. Neuromuscular Disorders, 2019, 29, S156. | 0.3 | 0 |
| 495 | Group medical appointments for people with physical illness. The Cochrane Library, 0, , . | 1.5 | 0 |
| 496 | CONGENITAL MYOPATHIES 1 â€“ NEMALINE. Neuromuscular Disorders, 2020, 30, S53. | 0.3 | 0 |
| 497 | CONGENITAL MYOPATHIES 1 â€“ NEMALINE. Neuromuscular Disorders, 2020, 30, S55. | 0.3 | 0 |
| 498 | FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S112-S113. | 0.3 | 0 |
| 499 | FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S113. | 0.3 | 0 |
| 500 | FSHD / OPMD / MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2020, 30, S113. | 0.3 | 0 |
| 501 | MYOTONIC DYSTROPHY. Neuromuscular Disorders, 2021, 31, S121. | 0.3 | 0 |
| 502 | FSHD. Neuromuscular Disorders, 2021, 31, S99-S100. | 0.3 | 0 |
| 503 | FSHD. Neuromuscular Disorders, 2021, 31, S100. | 0.3 | 0 |
| 504 | CONGENITAL MUSCULAR DYSTROPHIES. Neuromuscular Disorders, 2021, 31, S70. | 0.3 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | CONGENITAL MYOPATHIES. Neuromuscular Disorders, 2021, 31, S65. | 0.3 | 0 |
| 506 | 9a Addendum: neuralgische amyotrofie. , 2007, , 111-123. | | 0 |
| 507 | Addendum: neuralgische amyotrofie Een deel van de tekst van dit addendum is een bewerking van een artikel dat is gepubliceerd in het â€˜Neurologen Vademecumâ€™, uitgegeven door Bohn Stafleu van Loghum, Houten. Meer specifieke informatie is te vinden in eerder gepubliceerde Orthopedische CasuÃ¯stiek, 2002; addendum: neuralgische amyotrofie (Nens van Alfen, Baziel van Engelen). , 2010, , 391-397. | | 0 |
| 508 | AB0776â€…Muscle ultrasonography: a potential new diagnostic tool for inflammatory myopathies. , 2018, , . | | 0 |